Advertisement

Advertisement

LPCN Stock Latest News

Lipocine price target raised to $11 from $6.75 at Alliance Global

The FlyLipocine price target raised to $11 from $6.75 at Alliance Global

Lipocine Files Prospectus to Enable $50M Stock Offering

PremiumCompany Announcements

Lipocine Files Prospectus to Enable $50M Stock Offering

23d ago

LPCN Upcoming Earnings Report: What to Expect?

PremiumPre-Earnings

LPCN Upcoming Earnings Report: What to Expect?

25d ago

Lipocine Completes Phase 3 Trial for Postpartum Depression

PremiumCompany Announcements

Lipocine Completes Phase 3 Trial for Postpartum Depression

1M ago

Lipocine Updates Investor Presentation to Reflect Latest Strategy

PremiumCompany Announcements

Lipocine Updates Investor Presentation to Reflect Latest Strategy

1M ago

Lipocine announces last patient visit in Phase 3 trial of LPCN 1154

PremiumThe FlyLipocine announces last patient visit in Phase 3 trial of LPCN 1154

1M ago

Lipocine price target raised to $15 from $7 at H.C. Wainwright

The Fly

Lipocine price target raised to $15 from $7 at H.C. Wainwright

2M ago

Lipocine Completes Phase 3 Enrollment for Postpartum Depression Drug

Company Announcements

Lipocine Completes Phase 3 Enrollment for Postpartum Depression Drug

2M ago

Lipocine completes enrollment, dosing in Phase 3 trial of LPCN 1154

PremiumThe Fly

Lipocine completes enrollment, dosing in Phase 3 trial of LPCN 1154

2M ago

Lipocine updates investor presentation and corporate materials

PremiumCompany Announcements

Lipocine updates investor presentation and corporate materials

2M ago

Lipocine Advances Phase 3 Postpartum Depression Drug Trial

PremiumCompany Announcements

Lipocine Advances Phase 3 Postpartum Depression Drug Trial

2M ago

Lipocine: DSMB recommended Phase 3 LPCN 1154 continue as planned

PremiumThe Fly

Lipocine: DSMB recommended Phase 3 LPCN 1154 continue as planned

2M ago

Lipocine Advances Phase 3 Trial for PPD Treatment

PremiumCompany AnnouncementsLipocine Advances Phase 3 Trial for PPD Treatment

3M ago

Lipocine ‘s PPD Phase 3 study hits 80% enrollment milestone

The Fly

Lipocine ‘s PPD Phase 3 study hits 80% enrollment milestone

3M ago

Lipocine Showcases LPCN 2101 at Epilepsy Meeting

Company Announcements

Lipocine Showcases LPCN 2101 at Epilepsy Meeting

4M ago

Lipocine Announces Positive Interim Results for PPD Trial

PremiumCompany Announcements

Lipocine Announces Positive Interim Results for PPD Trial

4M ago

Lipocine Updates Corporate Presentation for Investors

PremiumCompany Announcements

Lipocine Updates Corporate Presentation for Investors

4M ago

PremiumThe Fly

Lipocine reports ‘promising’ safety profile in Phase 3 trial of LPCN 1154

4M ago

Lipocine price target lowered to $7 from $8 at H.C. Wainwright

PremiumThe Fly

Lipocine price target lowered to $7 from $8 at H.C. Wainwright

4M ago

Lipocine Inc. Reports Q3 2025 Financial Results

PremiumCompany AnnouncementsLipocine Inc. Reports Q3 2025 Financial Results

5M ago

Lipocine reports Q3 EPS (59c) vs. (44c) last year

The Fly

Lipocine reports Q3 EPS (59c) vs. (44c) last year

5M ago

Lipocine Presents Promising LPCN 2401 Data at ObesityWeek

Company Announcements

Lipocine Presents Promising LPCN 2401 Data at ObesityWeek

5M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >